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cells consume glutamine at large scale that is why there is lack
of glutamine in the skeletal muscle (Kulkarni et al., 2005). Glu-
tamine plays very important roles in tumor cell. Firstly it acts
as a nitrogen donor in the nucleotide and amino acid biosyn-
thesis, secondly glutamine helps in the uptake of essential ami-
no acid and it maintains the activation of TOR kinase (Wise
and Thompson, 2010). In many cancer cells, glutamine is the
primary mitochondrial substrate and it maintains mitochon-
drial membrane potential and integrity. It provides support
for the NADPH production needed for redox control and
macromolecular synthesis. Glutamine is the respiratory fuel
of tumor cells. Glutamic acid and glutamine both are inter
convertible. Glutamic acid comes under the major group of
neurotransmitters. It is the major work horse neurotransmitter
of the brain. It increases the brain function and mental activ-
ity. It detoxiﬁes the brain from ammonia by attaching itself
to nitrogen atoms in the brain and also helps in the transpor-
tation of potassium across the blood–brain barrier. It is con-
jectured that glutamate is involved in cognitive functions like
learning and memory in the brain, though excessive amounts
may cause neuronal damage associated with diseases like
amyotrophic lateral sclerosis, lathyrism and Alzheimer’s dis-
ease (Dutta et al., 2011).2. Glutamic acid as anticancer agent
L-Glutamic acid is converted into L-glutamine by L-glutamine
synthetase. L-glutamine biosynthesize purines and pyrimidinesby contributing 3- and 9-nitrogen groups of purine bases, 2-
amino group of guanine, 3-nitrogen group and amino group
of cytosine which are the bases of DNA and RNA (Dewald
and Moore, 1958). L-Glutamine cannot be synthesized in neo-
plastic cells due to the lower reactivity of L-glutamine synthe-
tase. Thus an antagonist of this enzyme can interfere with
the metabolic process of L-glutamine and act as anticancer
agents (Luzzio et al., 2000). Patients of cancer often develop
glutamine depletion in the muscles due to uptake by tumors
and chronic protein metabolism. On the basis of these, it can
be assumed that structural variants of glutamine might possess
possible antitumor activity.
L-Glutamic acid-c-(4-hydroxyanilide) is isolated from
mushroom Agaricus bisporous. It acts as a growth regulatory
substance for inhibiting the B16 melanoma cells in culture
(Srikanth et al., 2002). Azaserine and 6-diaza-5-oxo-L-norleu-
cine antagonized the metabolic process involving L-glutamine
and exhibited antitumor activity in animal models (Vishwana-
than et al., 2008). An aryl amide derivative of L-threo-c-hydro-
xy glutamic acid which is isolated from Justica ghiesbreghtiana
is active against various tumors (Nishiyama et al., 2001). The
synthetic amides of L-glutamic acid exhibit activity against
Ehrlich ascites carcinoma (Vila et al., 1990). Four N-(benzene-
sulfonyl)-L-glutamic acid bis(p-substituted phenylhydrazides)
have anticancer activity against PC-3 prostate cancer and in
COLO-205 colon cancer. L-Glutamic acid-c-monohydroxa-
mate (GAH) demonstrated complete cytotoxicity against L-
1210 cells in the culture and marked antitumoral activity
in vivo against L-1210 leukemia and B-16 melanoma (Xu
et al., 2005). Glutamate receptor is another important player
Figure 1 Chemical structures of CDDP, c-PGA, and PGA–CDDP conjugates.
Glutamic acid as anticancer agent: An overview 339in hippocampal long-term potentiation and memory. Glutamic
acid, a glutamate receptor agonist enhances retention of mem-
ory (Cui et al., 2009). Glutamic acid is also useful in lowering
blood pressure. According to a study by the Imperial College
of London, people who consume more glutamic acid have
low blood pressure than those who consume less (Stamler
et al., 2009). When the glutamine importer SLC1A5 is im-
paired then the uptake of essential amino acids is also impaired
and without the aid of essential amino acids rapamycin-sensi-
tive mTORC1 is not activated. mTORC1 is responsible for the
regulation of cell growth, protein translation and plays an
important role in inhibiting macro autophagy (Nicklin et al.,
2009). That means if mTORC1 is inactivated then there will
be no cell growth and no protein translation. In glioblastoma
cells, metabolism of glutamine provides the bulk of oxaloacetic
acid (OAA) cellular pool (DeBerardinis et al., 2007). This
OAA is one of the substrates in mitochondria that leads to
the synthesis of many essential biological macromolecules
like cholesterol (Hatzivassiliou et al., 2005). Hence glutamine
is the primary substrate in cancer cells that provides precursor
molecules to mitochondria for anaplerosis (replenishment of
the carbon pool). c-MYC (Myc), a DNA transcription factor
regulates three out of the ﬁve steps of purine and pyrimidine
synthesis at oncogenic level. It also promotes glutaminolysis
and this catabolism of glutamine leads to the larger amount
of carbon in the cell, which allows the cell to produce
more NADPH (Wise and Thompson, 2010). Since cancer
cells depend on glutamine lack of glutamine can lead to the
death of cancer cells. But as it is also required for some other
essential functions in the body such as in the brain therefore
that treatment should be adopted which can reduce the ability
of the cell to uptake glutamine by targeting Myc and other pro-
teins that are responsible for transporting glutamine into the
cell. L-c-Glutamyl-p-nitroanilide (GPNA) which inhibits
SLC1A5 (Esslinger et al., 2005) and BCH (2-aminobicyclo-
(2,2,1)heptanes carbozylic acid) which blocks mTORC1 (Nick-
lin et al., 2009) and that treatment which reprograms the
mitochondria so that it no longer depends on glutamine can
also be effective, e.g. amino-oxyacetic acid (AOA) is used be-cause it is a transaminase inhibitor (Moreadith and Lehninger,
1984).
3. Glutamic acid as conjugates with anticancer drug
Glutamic acid is used as a conjugate because it increases the
efﬁcacy of anticancer drug and decreases its toxicity toward
normal cells. Polyglutamic acid is biodegradable, edible and
nontoxic toward humans (Shih et al., 2004).
3.1. Conjugate with All-trans retinoic acid (ATRA)
ATRA is an active metabolite of vitamin A. It is used in the
treatment of acute promyelocytic leukemia and myelodysplas-
tic syndrome. It has a slow dissolution rate and low bioavail-
ability. Therefore to obtain ATRA with better solubility,
transportation and bioavailability, derivatives of ATRA con-
taining glutamic acid or its sodium salt were synthesized.
The two derivatives of ATRA, RAE and RAENa, exhibited
improved aqueous solubility and were more effective in mice
bearing S(180) tumors (Cui et al., 2009).
3.2. Conjugate with paclitaxel
Conjugation of paclitaxel and the water-soluble polyglutamate
is known as poly (L-glutamic acid)-paclitaxel (PG-TXL). Obser-
vations showed that PG-TXL has more antitumor activity than
free paclitaxel. PG-TXL exerts its anticancer activity by the con-
tinuous release of free paclitaxel into cells (Oldham et al., 2000).
3.3. Conjugate with cisplatin
Cisplatin [cis-dichlorodiammineplatinum (II), CDDP] is
combined with c-poly(a,L-glutamic acid) (c-PGA) to form
c-poly(a,L-glutamic acid)-cis-dichlorodiammineplatinum (c-PGA-
CDDP) which is water soluble. c-PGA–cisplastin conjugate
effectively inhibits human breast tumor cells xenografted into
nude mice. It also reduces the toxic side effects associated with
340 S. Dutta et al.the use of free CDDP and also produced desirable pharmaco-
kinetics and enhanced antitumor activity (Ye et al., 2006)
(Figure 1).
3.4. Conjugate with curcumin
Curcumin [diferuloylmethane; 1,7-bis-(4-hydroxyl-3-methoxy-
phenyl)-1,6-heptadiene-3,5-dione] is themajor pigmentary com-
ponent of turmeric (Curcuma longa). Curcumin with
nphthaloyl-glutamoylchloride forms 4,40-(di-o-glutamoyl)-
curcumin. According to a study curcumindiglutamoyl deriva-
tive was found to be more potent against cancer cell lines, HeLa
(cervical cancer) andKB (oral cancer), than other derivatives. It
is due to the activation of caspases which is facilitated due to
accumulation and better stability of diglutamiccurcumin (Du-
bey et al., 2008).
3.5. Conjugate with 20(s)-camptothecin (CPT)
Due to the instability of active lactone the therapeutic efﬁcacy
of 20(s)-camptothecin (CPT) is limited in humans. By binding
one molecule of a drug via the c-carboxylic acid of each mono-
meric subunit of poly-(L-glutamic acid) (PGA) it leads to the
stability of lactone. Linking of CPT to a high molecular weight
anionic polymer that is PGA enhances solubility and improves
distribution to the tumor through enhanced permeability and
retention (EPR effect) (Singer et al., 2001).
3.6. Conjugate with N-(4-hydroxyphenyl)retinamide (4HPR)
Several studies have indicated that N-(4-hydroxyphenyl)retina-
mide (4HPR) treatment is associated with the inhibition of
angiogenesis and a decreased vascular response in vitro and
in vivo. 4HPR was bound to a synthetic polyamino acid,
poly(L-glutamic acid) (PG). PG-4HPR was evaluated for its re-
lease kinetics and in vitro anti-proliferative and in vivo antitu-
mor activities against ovarian cancer cell lines. It was
conﬁrmed that treatments with both 4HPR and PG-4HPR de-
creased the expression of pre-angiogenic factor VEGF in
SKOV3 tumors. In-vivo, PG-4HPR demonstrated signiﬁcantly
enhanced antitumor activities compared to 4HPR in both early
treatment and later treatment protocols. Treatments with PG-
4HPR suppressed the expression of VEGF and reduced blood
ﬂow into the tumor (Zou et al., 2007).Figure 2 Transportation and metabolism of glutamine.4. Derivatives of glutamic acid as anticancer agent
4.1. Aminopteroylglutamic acid or pteroyl-L-glutamic acid
Aminopterin (4-aminopteroic acid), a 4-amino analog of folic
acid, is an antineoplastic drug with immunosuppressive prop-
erties used in chemotherapy (Oaks et al., 2010). Folate is in-
volved in DNA synthesis and methylation which may reduce
breast cancer risk, particularly among women with greater
alcohol consumption. High intake of folate may reduce the
risk of colon cancer (Giovannucci et al., 1998), but the dosage
and duration relations and the impact of diet compared with
supplementary sources are not well understood (Boehm
et al., 2009). Folate intake decreased the risk of pancreatic can-
cer in women but not in men (Percival et al., 2008).4.2. Methotrexate
Chemically methotrexate is N-[4-[[(2,4-diamino-6-pteridinyl)
methyl] methylamino] benzoyl]-L-glutamic acid. Methotrexate
tablets are used alone or in combination with other anticancer
agents in the treatment of breast cancer, epidermoid cancers of
the head and neck, advanced mycosis fungoides (cutaneous T-
cell lymphoma), and lung cancer, particularly squamous cell
and small cell types. Methotrexate tablets are also used in com-
bination with other chemotherapeutic agents in the treatment
of advanced stage non-Hodgkin’s lymphomas. It reduces dihy-
drofolates to tetrahydrofolates by the help of enzyme dihy-
drofolic acid reductase which inhibits the synthesis of purines
(Skeel, 2008).
4.3. L-Theanine
Chemically L-theanine is c-ethylamino-L-glutamic acid. Lim-
ited studies evaluate the effects of L-theanine in the prevention
of cancer. The observed anticancer effects are largely attrib-
uted to the catechins found in tea, while action on tumors
may be due to an enhanced immune response (McPhee et al.,
2011).
4.4. Thalidomide
It is a chemotherapeutic agent used against multiple myeloma,
myelodysplastic syndrome, leprosy etc. It acts by inhibiting
VEGF, TNF-a, GI growth factor, proliferation of NK cells
and stimulation of T-cells.
5. Transportation and metabolism of glutamine
Glutamine is the most abundant amino acid present in the
body. It is also known as levoglutamide, L-GA 5 amide, L-
(+)-2-aminoglutamic acid. Glutamine is formed in the body
from GA and ammonia in an energy requiring reaction cata-
lyzed by glutamine synthase (Kulkarni et al., 2005).
Glutamic acidþNH3 !Glutamine synthase Glutamine
Metabolism of glutamine takes place in the mitochondria.
Glutamine is transferred from the extra cellular medium of
mitochondria to the inner surface of mitochondria through
the speciﬁc plasma membrane. Malignant cells transport gluta-
mine across their plasma membranes at a faster rate than their
non-malignant cells. Malignant cells show an uncontrolled rate
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of precursor amino acids for biosynthesis. Therefore they
transport amino acids (glutamine) much faster than normal
cells (Medina et al., 1992). It has been seen in human
hepatoma cells which transport glutamine at a rate 10–20 times
faster than normal hepatocytes (Bannai and Ishii, 1988). Cyto-
plasm is ﬁlled with excess of glutamine, and glutamine is trans-
ported to mitochondria. In the mitochondria, glutamine is
acted upon by glutaminase, an enzyme requiring high phos-
phate concentrations to be fully active. The high concentra-
tions of inorganic phosphate found in the mitochondria of
tumor cells could explain the high activity of tumor glutamin-
ase in vivo. For cellular metabolism it is essential to transport
the amino acids through the plasma membrane. This transpor-
tation is mediated by proteins called carriers (Figure 2).
Glutamine is converted into glutamate and ammonia by
phosphate dependent glutaminase. This is the ﬁrst step in the
series of reaction that generates the metabolic intermediate
which is essential for cell growth. The high rate of intracellular
glutaminolysis results in high release of ammonia. Glutamine
is transported into cells mainly by sodium ion dependent sys-
tems A and ASC. After an excess of deposition of glutamine
in the cell cytoplasm it is transferred to mitochondria other-
wise it will be hydrolyzed by phosphate dependent
glutaminase.
6. Glutamate and its metabolism enzymes
The carboxylate anions and salts of glutamic acid are known
as glutamates. It is also important for metabolism.
6.1. Glutamine synthetase
It acts as a catalyst in this reaction
GlutamateþNH3 þATP! GlutamineþADP
The enzyme from mammalian brain has two important func-
tions: assimilation of ammonia and biosynthesis of glutamine
(Boksha et al., 1995).
6.2. Glutaminase
Glutaminase catalyzes the reaction of glutamine catabolism to
produce glutamate and ammonia. Its activity can be observed
both in neurones and astroglial cells, but glutaminase is more
active in neurons (Nimmo and Tipton, 1979), predominantly
in mitochondria. The enzyme becomes free from the inhibitory
inﬂuence of glutamate only when the concentration of glu-
tamic acid falls below normal values (Plaitakis et al., 1984).
6.3. Glutamate dehydrogenase
Glutamate dehydrogenase (GDH) catalyzes a reversible
reaction:
l-glutamic acidþH2OþNADðPÞ
$ 2OxoglutarateþNH3 þNADðPÞH
The GDH reaction is reversible but equilibrium is shifted clo-
ser to direct reaction (i.e. to synthesis of glutamic acid) (Zag-
anas et al., 2009). Consequently, GDH in brain takes part inthe synthesis of glutamate from 2-oxoglutaric acid, more than
in oxidation of the amino acid. This is the way of continuous
maintenance for changing of free ammonia into amino nitro-
gen of amino acids.
6.4. Aspartate transaminase or glutamate oxaloacetate
transaminase
Aspartate transaminase catalyzes the reversible transfer of
amino group to 2-oxoglutarate, as a result oxaloacetate and
glutamate are formed. This is the most active transaminase
in the brain (Kelly and Stanley, 2001). Oxaloacetate is quickly
transformed into malic acid which enters from the cytoplasm
into mitochondria. In this way the aspartate-malate bypath
for transfer redox equivalents from the cytosol to mitochon-
dria is formed. This bypath is the main way for transferring re-
dox equivalents to mitochondria in neurons. Inﬂux of
aspartate through the mitochondrial membrane is bound with
an efﬂux of a glutamate in such a way inﬂux of a malate is
bound with the efﬂux of 2-oxoglutarate, too.
6.5. Glutamic acid decarboxylase
Glutamic acid decarboxylase (GDA) catalyzes the separation
of a carboxylic group from glutamate with the formation of
gamma-aminobutyric acid (GABA). When GAD acts on glu-
tamate which has an excitatory inﬂuence on neurons, then
GABA is formed which is a main inhibitory neurotransmitter
in the brain (Kelly and Stanley, 2001).
7. Applications
7.1. Pharmacological uses of glutamic acid
7.1.1. Fuel
Glutamic acid takes part in more metabolic reactions than any
other amino acid. It is a source of glucose which is the chief
source of fuel. It maintains the normal blood glucose level
and also the acidity. It serves as a source of fuel for the intes-
tinal epithelium. Glutamine increases the body’s secretion of
human growth hormone (HGH). It also plays a major role
in removing excess ammonia from the bloodstream.
7.1.2. Muscle and other cell components
Glutamine is present in more than three-ﬁfths of the human
muscle tissue. It synthesizes both DNA and RNA and is essen-
tial for the synthesis of all proteins. By stimulating the release
of the anabolic hormone HGH, it plays an indirect role in
building the skeletal muscle. Glutamine also protects the integ-
rity of the gastrointestinal tract when ulcers, chemotherapy
agents or non-steroidal anti-inﬂammatory drugs are present.
7.1.3. Immune function
Glutamine is very essential for proper immune function. It is
required for the proliferation of lymphocytes and cytokines.
It increases the efﬁciency of macrophages, large immune cells
which engulf and degrade foreign substances ranging from
microbes to inorganic molecules. In many situations in which
the immune function is compromised, for example, severe
burns, sepsis or when athletes overexert themselves, gluta-
342 S. Dutta et al.mine depletion is at least partly responsible for the immune
suppression. The administration of glutamine to patients
receiving bone marrow transplants results in a lower inci-
dence of post-operative infections and a shorter stay in the
hospital.
7.1.4. Neurotransmitter
It is an important excitatory neurotransmitter. It helps in the
transportation of potassium across the blood–brain barrier.
It also shows promise in the future treatment of neurological
conditions, ulcers, hypoglycemic coma, muscular dystrophy,
epilepsy, Parkinson’s and mental retardation.
7.2. Other uses of glutamic acid
7.2.1. It is used as surfactants
It is hydrophilic by nature and can combine with hydrophobic
fatty acids easily to form molecules with both water-soluble
and water repelling portions that can be used as surfactants.
There are many applications of GA derivatives as surfactants,
especially due to its lack of harmful effects to skin and their
general smooth appearance. It is very much favored by the cos-
metic, moisture containing hair shampoo product
manufacturers.
7.2.2. It is used as buffer
GA is an amphopteric substance that contains both acidic and
basic functional groups and thus a natural buffer by itself.
7.2.3. It is used as Chelating agents
GA has two carboxylic groups, which can form chelates with
many metal cations. Such chelating reaction is useful in the re-
moval of heavy-metal contaminants in the wastewater treat-
ment processes.
7.2.4. It is used as ﬂavor enhancer
Monosodium glutamate (MSG), the single largest amino acid
product, has been used as a ﬂavor enhancer throughout the
world for the past forty years. MSG is used worldwide in huge
quantities as a ﬂavor enhancer in foods. MSG is known to pro-
duce a unique taste sensation termed ‘UMAMI’ the ﬁfth taste,
i.e. savory or brothy taste present in tomatoes and cheese. Free
glutamate content is said to increase during the process of nat-
ural ripening and brings about a fuller taste in many foods, the
basis behind is not known.7.2.5. It is used in culture medium
GA happens to be one of the main components in the cell wall
of Gram-positive bacteria. It is also one of the most essential
amino acids for other microorganisms to grow on. In most
cases, it is often necessary to add GA into culture media to ef-
fect normal growth.
7.2.6. It is used in agriculture
GA is one of the major amino acids in plant proteins and plays
a role of the major nitrogen storage for plants. That is why GA
is often one of the more prominent ingredients in many plant
growth supplements. Besides, GA is vital in the nitrogen
metabolism in plants.8. Overview and conclusion
The main objective of this article is to highlight the anticancer
activity of glutamic acid. From the above discussion it has
been concluded that glutamic acid is endogenic in nature hence
will produce a fewer side effects. Some times it is seen that it
increases the anticancer activity of that drug with which it is
combined, as in the case of c–poly (a,L-glutamic acid)-cis-
dichlorodiammineplatinum. This conjugate produces less side
effect and increased anticancer activity when compared with
cisplastin. Glutamine is the primary substrate in cancer cells
that provide precursor molecules which allows the cell to pro-
duce more NADPH. Since cancer cells depend on glutamine, if
glutamine synthesis and metabolism is blocked the anticancer
activity can be produced. But as glutamine is required for sev-
eral other functions of body like in the brain therefore block-
age of glutamine is not a smart way to achieve anticancer
activity. Rather the treatment should be done in such a way
which can reduce the ability of the cell to uptake glutamine,
such as by targeting Myc which is responsible for the synthesis
of purine and pyrimidine at oncogenic level and other proteins
that are responsible for transporting glutamine into the cell, or
drugs which block mTORC1. It is also a source of glucose,
essential for proper immune function. It also shows promise
in the future treatment of neurological conditions, ulcers,
hypoglycemic coma, muscular dystrophy, epilepsy, Parkin-
son’s, and mental retardation. Hence it can be concluded that
important therapeutic applications of glutamic acid are just
waiting to be discovered and can be implicated in cancer
treatment.
References
Bannai, S., Ishii, T., 1988. A novel function of glutamine in cell
culture: utilization of glutamine for the uptake of cystine in human
ﬁbroblast. J. Cell. Physiol. 137 (2), 360–366. http://dx.doi.org/
10.1002/jcp. 1041370221.
Boehm, K., Borrelli, F., Ernst, E., Habacher, G., Hung, S.K., Milazzo,
S., Horneber, M., 2009. Green tea (Camellia sinensis) for the
prevention of cancer. Cochrane Database Syst. Rev. (3),
CD005004. doi: 10.1002/14651858.CD005004.pub2.
Boksha, I.S., Tereshkina, E.B., Burbayeva, G.S., 1995. Isolation and
some properties of glutamine synthetase from human brain.
Biokhimiia (Mosc) 60 (10), 1697–1705 (Rus).
Cui, C., Zhang, Y., Wang, L., Liu, H., Cui, G., 2009. Enhanced
anticancer activity of glutamate prodrugs of all-trans retinoic acid.
J. Pharm. Pharmacol. 61 (10), 1353–1358. http://dx.doi.org/
10.1211/jpp. 61.10.0012.
DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff,
M., Wehrli, S., Thompson, C.B., 2007. Beyond aerobic glycolysis:
transformed cells can engage in glutamine metabolism that exceeds
the requirement for protein and nucleotide synthesis. Proc. Natl.
Acad. Sci. 104 (49), 19345–19350. http://dx.doi.org/10.1073/
pnas.0709747104.
Dewald, H.A., Moore, A.M., 1958. 6-Diazo-5-oxo-L-norleucine, a new
tumor-inhibitory substance. Preparation of L-, D- and DL-forms. J.
Am. Chem. Soc. 80 (15), 3941–3945. http://dx.doi.org/10.1021/
ja01548a036.
Dubey, S.K., Sharma, A.K., Narain, U., Misra, K., Pati, U., 2008.
Design, synthesis and characterization of some bioactive conjugates
of curcumin with glycine, glutamic acid, valine and demethylenated
piperic acid and study of their antimicrobial and antiproliferative
properties. Eur. J. Med. Chem. 43 (9), 1837–1846, <http://
dx.doi.org/10.1016/j.ejmech.2007.11.027>.
Glutamic acid as anticancer agent: An overview 343Dutta, S., Ray, S., Nagarajan, K., 2011. Glutamic acid analogues used
as potent anticancer: a review. Der Pharm. Chem. 3 (2), 263–272.
Esslinger, C.S., Cybulski, K.A., Rhoderick, J.F., 2005. Nc-Aryl
glutamine analogues as probes of the ASCT2 neutral amino acid
transporter binding site. Bioorg. Med. Chem. 13 (4), 1111–1118,
<http://dx.doi.org/10.1016/j.bmc.2004.11.028>.
Giovannucci, E., Stampfer, M.J., Colditz, G.A., Hunter, D.J., Fuchs,
C., Rosner, B.A., Speizer, F.E., Willett, W.C., 1998. Multivitamin
use, folate and colon cancer in women in the Nurses’ health study.
Ann. Intern. Med. 129 (7), 517–524.
Hatzivassiliou, G., Zhao, F., Bauer, D.E., Andreadis, C., Shaw, A.N.,
Dhanak, D., Hingorani, S.R., Tuveson, D.A., Thompson, C.B.,
2005. ATP citrate lyase inhibition can suppress tumor cell growth.
Cancer Cell 8 (4), 311–321, <http://dx.doi.org/10.1016/
j.ccr.2005.09.008>.
Kelly, A., Stanley, C.A., 2001. Disorders of glutamate metabolism.
Ment. Retard. Dev. Disabil. Res. Rev. 7 (4), 287–295. http://
dx.doi.org/10.1002/mrdd.1040.
Kulkarni, C., Kulkarni, K.S., Hamsa, B.R., 2005. L-Glutamic acid and
glutamine: exciting molecules of clinical interest. Indian J. Phar-
macol. 37 (3), 148–154. http://dx.doi.org/10.4103/0253-7613.16210.
Luzzio, F.A., Mayorov, A.V., Figg, W.D., 2000. Thalidomide metab-
olites. Part 1: derivatives of (+)-2-(N-phthalimido)-c-hydroxyglu-
tamic acid. Tetrahedron Lett. 41 (14), 2275–2278, <http://
dx.doi.org/10.1016/S0040-4039(00)00160-X>.
McPhee, S.J., Papadakis, M.A., Rabow, M.W., 2011. Current Medical
Diagnosis and Treatment 2011, 50 ed. Lange Medical Books/
McGraw-Hill, New York.
Medina, M.A., Sanchez-Jimenez, F., Marquez, J., Quesada, A.R.,
Castro, I.N., 1992. Relevance of glutamine metabolism to tumour
cell growth. Mol. Cell. Biochem. 113 (1), 1–15.
Moreadith, R.W., Lehninger, A.L., 1984. The pathways of glutamate
and glutamine oxidation by tumor cell mitochondria. Role of
mitochondrial NAD(P)+-dependent malic enzyme. J. Biol. Chem.
259 (10), 6121–6215.
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H.,
Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., Myer, V.E.,
MacKeigan, J.P., Porter, J.A., Wang, Y.K., Cantley, L.C., Finan,
P.M., Murphy, L.O., 2009. Bidirectional transport of amino acids
regulates mTOR and autophagy. Cell 136 (3), 521–534, <http://
dx.doi.org/10.1016/j.cell.2008.11.044>.
Nimmo, G.A., Tipton, K.F., 1979. The distribution of soluble and
membrane-bound forms of glutaminase in pig brain. J. Neurochem.
33 (5), 1083–1084. http://dx.doi.org/10.1111/j.1471-4159.1979.
tb05245.x.
Nishiyama, N., Kato, Y., Sugiyama, Y., Kataoka, K., 2001. Cisplatin-
loaded polymer–metal complex micelle with time-modulated
decaying property as a novel drug delivery system. Pharm. Res.
18 (7), 1035–1041.
Oaks, B.M., Dodd, K.W., Meinhold, C.L., Jiao, L., Church, T.R.,
Stolzenberg-Solomon, R.Z., 2010. Folate intake, post-folic acid
grain fortiﬁcation, and pancreatic cancer risk in the prostate, lung,
colorectal and ovarian cancer screening trial. Am. J. Clin. Nutr. 91
(2), 449–455. http://dx.doi.org/10.3945/ajcn.2009.28433.
Oldham, E.A., Lic, K.S., Wallace, S., Huang, P., 2000. Comparison of
action of paclitaxel and poly(L-glutamic acid)–paclitaxel conjugate
in human breast cancer cells. Indian J. Oncol. 16, 125–132.Percival, S.S., Bukowski, J.F., Milner, J., 2008. Bioactive food
components that enhance cd T cell function may play a role in
cancer prevention. J. Nutr. 138 (1), 1–4.
Plaitakis, A., Berl, S., Yahr, M.D., 1984. Neurological disorders
associated with deﬁciency of glutamate dehydrogenase. Ann.
Neurol. 15 (2), 144–153. http://dx.doi.org/10.1002/ana.410150206.
Shih, I.L., Van, Y.T., Shen, M.H., 2004. Biomedical applications of
chemically and microbiologically synthesized poly(glutamic acid)
and poly(lysine). Mini Rev. Med. Chem. 4 (2), 179–188.
Singer, J.W., Bhatt, R., Tulinsky, J., Buhler, K.R., Heasley, E., Klein,
P., de, Vries.P., 2001. Water-soluble poly-(L-glutamic acid)-gly-
camptothecin conjugates enhance camptothecin stability and efﬁ-
cacy in vivo. J. Controlled Release 74 (1–3), 243–247, <http://
dx.doi.org/10.1016/S0168-3659(01)00323-6>.
Skeel, R.T., 2008. Hand Book of Cancer Chemotherapy, seventh ed.
Lippincott, Williams & Wilkins, New York.
Srikanth, K., Kumar, C.A., Ghosh, B., Jha, T., 2002. Synthesis,
screening and quantitative structure-activity relationship (QSAR)
studies of some glutamine analogues for possible anticancer
activity. Bioorg. Med. Chem. 10 (7), 2119–2131, <http://
dx.doi.org/10.1016/S0968-0896(02)00079-2>.
Stamler, J., Brown, I.J., Daviglus, M.L., Chan, Q., Kesteloot, H.,
Ueshima, H., Zhao, L., Elliott, P., 2009. Glutamic acid––the main
dietary amino acid and blood pressure: the INTERMAP study
(international collaborative study of macronutrients, micronutri-
ents and blood pressure). Circulation 120 (3), 221–228. http://
dx.doi.org/10.1161/CIRCULATIONAHA.108.839241.
Vila, J., Thomasset, N., Navarro, C., Dore´, J.F., 1990. In vitro and
in vivo anti-tumor activity of L-glutamic acid c-monohydroxamate
against L1210 leukemia and B16 melanoma. Int. J. Cancer 45 (4),
737–743. http://dx.doi.org/10.1002/ijc.2910450428.
Vishwanathan, C.L., Deb, S., Jain, A., Lokhande, T., Juvekar, A.,
2008. Synthesis and evaluation of L-glutamic acid analogs as
potential anticancer agents. Indian J. Pharm. Sci. 70 (2), 245–249.
http://dx.doi.org/10.4103/0250-474X.41467.
Wise, D.R., Thompson, C.B., 2010. Glutamine addiction: a new
therapeutic target in cancer. Trends Biochem. Sci. 35 (8), 427–433,
<http://dx.doi.org/10.1016/j.tibs.2010.05.003>.
Xu, H., Jiang, M., Li, H., Lu, D., Ouyang, P., 2005. Efﬁcient
production of poly(c-glutamic acid) by newly isolated Bacillus
subtilis NX-2. Process Biochem. 40 (2), 519–523, <http://
dx.doi.org/10.1016/j.procbio.2003.09.025>.
Ye, H., Jin, L., Hu, R., Yi, Z., Li, J., Wu, Y., Xi, X., Wu, Z., 2006. Poly
(c,L-glutamic acid)–cisplatin conjugate effectively inhibits human
breast tumor xenografted in nude mice. Biomaterials 27 (35), 5958–
5965, <http://dx.doi.org/10.1016/j.biomaterials.2006.08.016>.
Zaganas, I., Kanavouras, K., Mastorodemos, V., Latsoudis, H.,
Spanaki, C., Plaitakis, A., 2009. The human GLUD2 glutamate
dehydrogenase: localization and functional aspects.Neurochem. Int.
55 (1-3), 52–63, <http://dx.doi.org/10.1016/j.neuint.2009.03.001>.
Zou, C., Brewer, M., Cao, X., Zang, R., Lin, J., Deng, Y., Li, C., 2007.
Antitumor activity of 4-(N-hydroxyphenyl) retinamide conjugated
with poly (L-glutamic acid) against ovarian cancer xenografts.
Gynecol. Oncol. 107 (3), 441–449, <http://dx.doi.org/10.1016/
j.ygyno.2007.07.077>.
